What is HC Wainwright’s Estimate for Pharvaris Q3 Earnings?

Pharvaris N.V. (NASDAQ:PHVS) – Research analysts at HC Wainwright issued their Q3 2025 earnings estimates for Pharvaris in a research report issued to clients and investors on Wednesday, October 15th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of ($0.69) for the quarter. HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Pharvaris’ Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.31) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.87) EPS, Q4 2026 earnings at ($0.91) EPS, FY2026 earnings at ($3.42) EPS, FY2027 earnings at ($2.67) EPS, FY2028 earnings at ($0.72) EPS and FY2029 earnings at $2.22 EPS.

A number of other brokerages have also commented on PHVS. Zacks Research upgraded shares of Pharvaris from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th. Bank of America upgraded shares of Pharvaris from an “underperform” rating to a “neutral” rating and lifted their price target for the stock from $16.00 to $27.00 in a report on Thursday, October 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a report on Wednesday, October 8th. Finally, JMP Securities lowered their target price on shares of Pharvaris from $55.00 to $52.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 13th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $37.17.

Pharvaris Stock Performance

Shares of NASDAQ:PHVS opened at $21.12 on Friday. The firm has a market cap of $1.10 billion, a PE ratio of -6.29 and a beta of -2.77. The firm’s fifty day moving average is $23.03 and its 200-day moving average is $19.36. Pharvaris has a 52 week low of $11.51 and a 52 week high of $26.33.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.07).

Institutional Investors Weigh In On Pharvaris

Several hedge funds and other institutional investors have recently bought and sold shares of PHVS. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in Pharvaris in the second quarter valued at $57,000. JPMorgan Chase & Co. increased its stake in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc increased its stake in Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after purchasing an additional 1,695 shares in the last quarter. Palumbo Wealth Management LLC increased its stake in Pharvaris by 38.0% in the first quarter. Palumbo Wealth Management LLC now owns 14,102 shares of the company’s stock valued at $221,000 after purchasing an additional 3,881 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in Pharvaris by 9.8% in the second quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock valued at $247,000 after purchasing an additional 1,257 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.